Worth reading
70In focus
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
2400000
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
11th Stock Acquisition Rights issued through third-party allocation (with exercise price adjustment clause)
Who receives how much
Shares delivered during the month: 2,400,000 shares (2,400,000 new shares and 0 treasury shares transferred)
EVO FUND (issued on 26 December 2025)
The lower thin line represents the existing number of shares to which these shares will be added.
Existing Shares and Increase
+3.20%Rate of increase
81,555,233 shares83,955,233Shares
2,400,000 shares delivered during the month; exercise ratio subject to exercise restrictions: 3.2% (based on 75,355,233 shares listed as outstanding at the time of payment for the issuance)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
Exercise price during the month: ¥44 on 2 March 2026, ¥42 on 17 and 18 March, and ¥40 on 25 and 26 March. Details of the adjustment clause and the lower limit: Not disclosed
Number of Stock Acquisition Rights
Total number issued: 700,000; exercised during the month: 24,000; unexercised at the end of the previous month: 638,000; unexercised at month-end: 614,000
Procedures under the Corporate Code of Conduct
The disclosure describes compliance with the exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments
Most recent equity financing
26 December 2025: Issuance of the 11th Stock Acquisition Rights, with EVO FUND as the allottee (detailed amount: Not disclosed)
| Item | Details |
|---|---|
| Type of issuance or disposal | 11th Stock Acquisition Rights issued through third-party allocation (with exercise price adjustment clause) |
| Number of shares to be issued or disposed of | Shares delivered during the month: 2,400,000 shares (2,400,000 new shares and 0 treasury shares transferred) |
| Intended allottee | EVO FUND (issued on 26 December 2025) |
| Dilution Rate | 2,400,000 shares delivered during the month; exercise ratio subject to exercise restrictions: 3.2% (based on 75,355,233 shares listed as outstanding at the time of payment for the issuance) |
| Total number of issued shares | As of the end of the previous month: 81,555,233 shares → As of the end of the month: 83,955,233 shares (the number obtained by adding the 2,400,000 new shares delivered during the month to the number of shares outstanding at the end of the previous month) |
| Exercise price | Exercise price during the month: ¥44 on 2 March 2026, ¥42 on 17 and 18 March, and ¥40 on 25 and 26 March. Details of the adjustment clause and the lower limit: Not disclosed |
| Number of Stock Acquisition Rights | Total number issued: 700,000; exercised during the month: 24,000; unexercised at the end of the previous month: 638,000; unexercised at month-end: 614,000 |
| Procedures under the Corporate Code of Conduct | The disclosure describes compliance with the exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments |
| Most recent equity financing | 26 December 2025: Issuance of the 11th Stock Acquisition Rights, with EVO FUND as the allottee (detailed amount: Not disclosed) |
Items this document does not state (19)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the monthly exercise status of the 11th Stock Acquisition Rights in March 2026.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.